Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 15.02M
shares outstanding. The number of shares has increased by -0.42%
in one year.
| Shares Outstanding | 15.02M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 9,180 |
| FTD / Avg. Volume | 3.41% |
Short Selling Information
The latest short interest is 1.79M, so 11.92% of the outstanding
shares have been sold short.
| Short Interest | 1.79M |
| Short % of Shares Out | 11.92% |
| Short % of Float | 12.07% |
| Short Ratio (days to cover) | 9.52 |
Valuation Ratios
The PE ratio is -4.38 and the forward
PE ratio is -1.14.
Jasper Therapeutics's PEG ratio is
0.21.
| PE Ratio | -4.38 |
| Forward PE | -1.14 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 5.06 |
| P/FCF Ratio | -4.94 |
| PEG Ratio | 0.21 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Jasper Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.98 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,113,578.12 |
| Employee Count | 64 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.49M |
| Effective Tax Rate | 2.05% |
Stock Price Statistics
The stock price has increased by -77.94% in the
last 52 weeks. The beta is 2.56, so Jasper Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.56 |
| 52-Week Price Change | -77.94% |
| 50-Day Moving Average | 4.89 |
| 200-Day Moving Average | 14.37 |
| Relative Strength Index (RSI) | 62.72 |
| Average Volume (20 Days) | 269,335 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -76.24M |
| Net Income | -71.27M |
| EBITDA | -71.39M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.89 |
Full Income StatementBalance Sheet
The company has 71.64M in cash and 1.81M in
debt, giving a net cash position of 69.82M.
| Cash & Cash Equivalents | 71.64M |
| Total Debt | 1.81M |
| Net Cash | 69.82M |
| Retained Earnings | -240.87M |
| Total Assets | 79.9M |
| Working Capital | 60.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -62.6M
and capital expenditures -552K, giving a free cash flow of -63.15M.
| Operating Cash Flow | -62.6M |
| Capital Expenditures | -552K |
| Free Cash Flow | -63.15M |
| FCF Per Share | -4.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
